News - AMAG Pharmaceuticals, Hematology

Filter

Popular Filters

1 to 25 of 54 results

Positive Ph III pediatric data for investigational hemophilia A drug Eloctate

Positive Ph III pediatric data for investigational hemophilia A drug Eloctate

10-04-2014

US biotech firm Biogen Idec and Swedish Orphan Biovitrum today released positive top-line results of…

Biogen IdecEloctateHematologyResearchSwedish Orphan Biovitrum

Baxter to acquire Chatham Therapeutics for $70 million

03-04-2014

USA-based Baxter International says it has agreed to acquire Chatham Therapeutics, a private biotechnology…

Baxter InternationalBiotechnologyChatham TherapeuticsHematologyMergers & Acquisitions

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

US FDA clears Biogen Idec and SOBI’s Alprolix for hemophilia B

31-03-2014

Marking a second regulatory hurdle for the breakthrough product, the US Food and Drug Administration…

AlprolixBenefixBiogen IdecBiotechnologyCSL LimitedHematologyNorth AmericaNovo NordiskPfizerRegulationSwedish Orphan BiovitrumUSA

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

21-03-2014

US biotech firm Biogen Idec has announced that Health Canada has approved Alprolix for the control and…

AlprolixBiogen IdecCanadaHematologyPharmaceuticalRegulation

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

Emmaus Life Sciences releases top Phase III results for sickle cell anemia treatment

20-03-2014

US biotech company Emmaus Life Sciences, which focuses on orphan diseases, has announced preliminary…

BiotechnologyHematologyResearchUSA

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Bayer to invest 500 million-euro-plus in hemophilia products manufacturing in Germany

Bayer to invest 500 million-euro-plus in hemophilia products manufacturing in Germany

12-03-2014

German pharma major Bayer revealed yesterday that it plans an investment of more than 500 million euros…

BayerFinancialGermanyHematologyNorthern EuropePharmaceuticalProduction

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Cumberland Pharma acquires Vaprisol from Astellas

03-03-2014

USA-based Cumberland Pharmaceuticals says it has acquired from the US subsidiary of Japan’s Astellas…

Astellas PharmaCumberland PharmaceuticalsHematologyLicensingNorth AmericaPharmaceuticalUSAVaprisol

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

03-03-2014

The US Food and Drug Administration has granted orphan drug designation to US drugmaker OPKO Health’s…

HematologyNorth AmericaOPKO HealthPharmaceuticalRare diseasesUSA

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Positive Ph III results with Bayer’s long-acting recombinant factor VIII product BAY94-9027

Positive Ph III results with Bayer’s long-acting recombinant factor VIII product BAY94-9027

18-02-2014

Germany’s Bayer has released positive results from the PROTECT VIII trial evaluating the company’s…

BAY94-9027BayerHematologyPharmaceuticalResearch

Australia’s CSL posts solid half-year results

Australia’s CSL posts solid half-year results

13-02-2014

Australian blood products and vaccine maker CSL reported a 3% rise in net profit to $646 million (all…

CSL LimitedFinancialHematologyPharmaceuticalVaccines

La Jolla Pharma gains hepcidin agonists rights from INSERM

12-02-2014

San Diego, USA-based drug developer La Jolla Pharmaceutical has entered into an exclusive worldwide license…

HematologyLa Jolla PharmaceuticalLicensingPharmaceuticalResearch

$20 million milestones for MacroGenics from Servier

$20 million milestones for MacroGenics from Servier

06-02-2014

Servier, France’s largest privately‐held pharmaceutical company, has exercised its exclusive option…

FinancialHematologyLicensingMacroGenicsMGD006OncologyPharmaceuticalServier

Baxter restructures deal with Xenetic Biosciences

31-01-2014

USA-based Baxter International has restructured its ongoing agreement with Xenetic Biosciences for the…

BAX 826Baxter InternationalHematologyLicensingPharmaceuticalResearchXenetic Biosciences

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Swedish company Dilaforette announces Sobi’s Christina Herder as new CEO

22-01-2014

Swedish drug development company Dilaforette has named Christina Herder as its new chief executive.

BoardroomDilaforetteHematologyNorthern EuropePharmaceuticalSobi

Galena Biopharma acquires Mills Pharmaceuticals

14-01-2014

US drugmaker Galena Biopharma revealed that it has acquired Mills Pharmaceuticals, which has the worldwide…

AnagrelideGalena BioPharmaHematologyMergers & AcquisitionsMills PharmaceuticalsPharmaceutical

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

Biogen Idec and Sangamo BioSciences collaborate on blood disorder therapeutics

10-01-2014

US biotech firm Biogen Idec and Sangamo Biosciences have signed an exclusive worldwide collaboration…

Biogen IdecBiotechnologyHematologyLicensingResearchSangamo BioSciences

Shield Therapeutics’ ST10 delivers robust results in AEGIS Ph III program

07-01-2014

Independent UK pharma firm Shield Therapeutics has announces strongly positive top-line data from the…

HematologyInflammatory diseasesPharmaceuticalResearchShield TherapeuticsST10

New Zealand to fully subsidize Abbott Lab’s Ferrograd

New Zealand to fully subsidize Abbott Lab’s Ferrograd

06-01-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has approved an agreement with the local subsidiary…

Abbott LaboratoriesAsia-PacificFerrogradFinancialHematologyPharmaceutical

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

FDA approves Novo Nordisk’s Tretten to treat rare genetic clotting disorder

24-12-2013

The US Food and Drug Administration yesterday (December 23) approved Tretten, coagulation factor XIII…

HematologyNorth AmericaNovo NordiskNovoThirteenPharmaceuticalRare diseasesRegulationTretten

1 to 25 of 54 results

Back to top